Close this search box.

New chair, CFO for I-Mab as part of U.S. push

ARTICLE | Management Tracks

Plus: Artios hires Silverstein as CFO and updates from Astellas, atai, Cartography, Corvus and Helio

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst

February 8, 2024 3:20 AM UTC

I-Mab Biopharma (NASDAQ:IMAB) appointed Pamela Klein as interim chair and named Joseph Skelton as CFO, as it divests its assets and operations in China as part of its plan to become a U.S. biotech. Klein and Skelton succeed Jingwu Zang and Richard Yeh, respectively. Zang is stepping down to lead I-Mab Biopharma (Hangzhou) Co. Ltd., and Yeh has resigned, along with Andrew Zhu, who was I-Mab’s president. Skelton was SVP of Truist Securities, and previously held roles at Cantor Fitzgerald and Amneal Pharmaceuticals Inc.

Artios Pharma Ltd. hired Christine Silverstein as CFO, an appointment that could signal the company’s intent to go public. Silverstein worked on IPO planning as CFO at Excision BioTherapeutics Inc. and Emendo Biotherapeutics Inc. Artios is exploring synthetic lethal targets outside of homologous recombination. …